First Rounders - TopPodcast.com

View Top 200 Chart

Back to Rankings Page

First Rounders — Natural Sciences
First Rounders

Nature Biotechnology‘s First Rounders podcast is a series of conversations with founders, financers and developers from biotech’s past, present and future.

Hosted on Acast. See acast.com/privacy for more information.

Copyright: © 2019 Springer Nature 878632

Latest Episodes:

Grace Colón Jan 02, 2021

Show notes

Grace Colón is president and CEO of InCarda Therapeutics. Her conversation with Nature Biotechnology covers growing up in San Juan, Puerto Rico; her love of musical theater; and how grad school at MIT guided her toward a career in entrepreneurship.

Hosted on Acast. See acast.com/privacy for more information.

Tillman Gerngross Nov 01, 2020

Show notes

Tillman Gerngross is the CEO and co-founder of Adimab, and a professor of bioengineering at Dartmouth College. His conversation with Nature Biotechnology covers his years at GlycoFi, the nature of problem solving in entrepreneurship, and Adimab’s paper last year challenging the work of MIT researcher Ram Sasisekharan.

Editor's note: Ram Sasisekharan has since been cleared of these charges. Please see https://www.statnews.com/2023/06/14/ram-sasisekharan-mit-vindicated-fraud-investigation/ and https://www.wsj.com/articles/mit-drug-researcher-cleared-in-research-probe-3d050624?utm_source=headtopics&utm_medium=news&utm_campaign=2023-06-15 for more information.

Hosted on Acast. See acast.com/privacy for more information.

Noubar Afeyan Sep 01, 2020

Show notes

Noubar Afeyan is the founder and CEO of Flagship Pioneering. His conversation with Nature Biotechnology covers his family fleeing the Lebanese Civil War when he was a boy, how a chance encounter at a scientific meeting opened his mind to entrepreneurism, and why immigrants (and entrepreneurs) benefit from having a “paranoid optimist” mindset.

Hosted on Acast. See acast.com/privacy for more information.

Katrine Bosley Jul 01, 2020

Show notes

Katrine Bosley is former CEO of Editas Medicines and Avila Therapeutics. She discusses growing up in Ohio, her first job in biotech (as an administrative assistant) and why her five years at CRISPR company Editas felt more like 1,000. This episode is part of Nature Biotechnology's focus issue on translating the CRISPR technology.

Hosted on Acast. See acast.com/privacy for more information.

Ted Love Jun 22, 2020

Show notes

Ted Love is the president and CEO of Global Blood Therapeutics. In his conversation with Nature Biotechnology, he discusses why his time at Haverford College was transformative, why he views Global Blood Therapeutics as a social justice company, and what might be gained from the “racial catharsis” happening in America after the police killing of George Floyd.

Hosted on Acast. See acast.com/privacy for more information.

Alexis Borisy May 01, 2020

Show notes

Alexis Borisy is CEO and Chairman of EQRx, and a long-time biotech builder with Third Rock Ventures. His conversation with Nature Biotechnology covers growing up as a “faculty brat” in Wisconsin, dropping out of his PhD program at Harvard and why, even as an investor, biotech cannot be all about the money.

Hosted on Acast. See acast.com/privacy for more information.

Bonus: Jeremy Levin Apr 22, 2020

Show notes

A conversation with Jeremy Levin, chairman of the Biotechnology Innovation Organization and CEO of Ovid Therapeutics, about industry versus government responses to covid19, the split within biotech on how to address charges of high prices, and why the biopharma industry is so disliked.

Hosted on Acast. See acast.com/privacy for more information.

Bassil Dahiyat Mar 02, 2020

Show notes

Bassil Dahiyat is co-founder, president and CEO of Xencor. His conversation with Nature Biotechnology covers his parents emigrating from Jordan, how Xencor has survived (and changed) over the past 22 years, and when it’s necessary for a CEO to speak out.

Hosted on Acast. See acast.com/privacy for more information.

Forum: Schneeberger on Clavien Jan 14, 2020

Show notes

Senior Editor Irene Jarchum talks to Stefan Schneeberger about the significance of a recent Nature Biotechnology paper describing a sophisticated perfusion machine to keep human livers alive for a week. The work was carried out by Pierre-Alain Clavien and colleagues from ETH Zurich. Read the paper here.

Hosted on Acast. See acast.com/privacy for more information.

Greg Verdine Jan 02, 2020

Show notes

Greg Verdine is a professor at Harvard University, and CEO and president of FogPharma and LifeMine Therapeutics. He is co-founder of more than 10 companies. His talk with Nature Biotechnology covers growing up in the Pine Barrens of New Jersey, the importance of excelling in the lab versus the classroom, and drugging the undruggable.

Hosted on Acast. See acast.com/privacy for more information.

Related Podcasts